What Was Known and When
Abstract
Five cases follow in which federal health agencies, a grantee or a manufacturer held information about a hazard before the public did. Each case gives the date the hazard was known, who knew it, what was done, and what the public was told. In 1955 an NIH scientist's finding that Cutter vaccine lots paralyzed monkeys did not reach the licensing committee. From 1960 officials knew polio vaccine carried SV40; they screened new lots and recalled none, and contaminated stock stayed in use into 1963. EcoHealth Alliance reported a Wuhan experiment that made mice sicker nearly two years late. The myocarditis signal appeared in CDC data in 2021, and FDA put age-specific risk figures and evidence of persistent heart injury on the labels in 2025. According to reports of a Health Canada email, Pfizer filed its plasmid sequence with Health Canada without identifying the SV40 element in it.
7.1 Cutter: a warning that stopped inside NIH
Before Cutter's polio vaccine was licensed, an NIH scientist found that half the Cutter lots she tested paralyzed monkeys. Her results did not reach the licensing committee.
Bernice Eddy, a scientist at the NIH Laboratory of Biologics Control, tested Cutter Laboratories' Salk vaccine in monkeys. Three of the six lots she tested paralyzed the animals, which showed that they contained live poliovirus. She reported the results to the laboratory's chief, William Workman. Accounts also name NIH director William Sebrell as having received and set aside the results. The findings were not passed to the vaccine licensing advisory committee.
Evidence: Exhibit 106, Exhibit 107, Exhibit 108, Exhibit 072
Mechanism: Known inside, disclosed late
The date of Eddy's tests is uncertain. Some accounts place them in 1954 and others in the spring of 1955. Either date falls before 12 April 1955, when the committee recommended Cutter for a license on the same day the Francis field-trial results were announced. The National Library of Medicine holds a 1986 oral-history interview with Eddy whose listed topics include "the Cutter scandal" and "holding back her polio vaccine research."
Paralysis among Cutter vaccinees began within weeks. A CDC surveillance report of May 1955 associated the cases with Cutter's vaccine. The casualties among vaccinated children and their contacts are set out in Finding 5.1. On 29 April 1955 Sebrell chaired a meeting on the incident that produced no conclusion on what Cutter should change in its manufacturing.
A congressional hearing in June 1955 concluded that the problem lay chiefly in the Laboratory of Biologics Control's lack of scrutiny. Secretary of Health, Education, and Welfare Oveta Culp Hobby stepped down. Sebrell resigned as NIH director. Workman was removed as head of the laboratory and stayed at NIH as Chief of the Laboratory of Control Activities until he retired in 1963,, according to a secondary account.
Exhibit 106 · Laboratory test record, known secondhand
Bernice Eddy's safety tests of Cutter polio vaccine lots
Eddy, a scientist at the NIH Laboratory of Biologics Control, tested Cutter Laboratories' Salk vaccine in monkeys and found that three of six lots paralyzed them, showing live poliovirus. She reported the results to the laboratory's chief, William Workman. The results were not passed to the vaccine licensing advisory committee, which recommended Cutter for licensure on 12 April 1955. On 29 April 1955 NIH director William Sebrell chaired a meeting on the incident that produced no conclusion on what Cutter should change in its manufacturing.
- Source
- Laboratory of Biologics Control, National Institutes of Health; known through Wikipedia, "Bernice Eddy"
- Date
- 1954 or spring 1955 (accounts differ)
- Grade
- Reported
- Document
- https://en.wikipedia.org/wiki/Bernice_Eddy
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
- Note
- Secondary. Accounts disagree on the test date: Wikipedia has given 1954; other accounts place the tests in spring 1955, before licensure. Some accounts say NIH director William Sebrell also disregarded the results and that Eddy's photographs of paralyzed monkeys were not returned.
7.2 SV40: discovery and the decision not to recall
Federal officials knew by 1960 that polio vaccine carried SV40. They ordered new lots screened in 1961, recalled no existing stock, and certified every lot free of the virus only from 1963.
Polio vaccine was grown in rhesus monkey kidney cells. In 1960 Ben Sweet and Maurice Hilleman of Merck isolated a monkey virus in those cultures and named it SV40. According to Bookchin and Schumacher, on 6 July 1960 Eddy reported to her chief, Joseph Smadel, that extracts of the same cells caused cancers in hamsters. In 1961 federal officials ordered manufacturers to screen new vaccine for SV40. They recalled no existing stock.
Evidence: Exhibit 111, Exhibit 110, Exhibit 112, Exhibit 109
Mechanism: Known inside, disclosed late
The dating of Eddy's hamster finding differs between sources. Bookchin and Schumacher, working from her correspondence, give 6 July 1960. James Goedert of the National Cancer Institute told Congress in 2003 that Eddy detected cancer in newborn hamsters in 1961. According to Bookchin and Schumacher, after Eddy presented the work at a New York cancer meeting in October 1960, she was denied permission to attend scholarly conferences, her papers were held up, and she was removed from vaccine research. They reproduce correspondence among Eddy, Smadel and Division of Biologics Standards chief Roderick Murray in an appendix.
CDC states that after the contamination was discovered, the government set testing requirements to verify that all new lots were free of SV40. Barbara Loe Fisher testified in 2003 that contaminated Salk stocks continued to be given to American children until early 1963. Goedert, for the National Cancer Institute, testified that "since 1963 every lot of vaccine has been tested and certified as free of SV-40." Lots released before 1963 were not all certified.
Exhibit 111 · Congressional hearing transcript
The SV-40 Virus: Has Tainted Polio Vaccine Caused an Increase in Cancer? (Serial No. 108-85)
They did contain SV-40 because there are test results that I have, which now the committee has, that show the positive vacuolating agent in released product.
James Goedert of the National Cancer Institute testified that in 1961 Bernice Eddy detected cancer in newborn hamsters injected with the vaccine preparation, and that "since 1963 every lot of vaccine has been tested and certified as free of SV-40." He testified that Howard Strickler was a former postdoctoral fellow from his branch with whom the branch had collaborated until recently. Barbara Loe Fisher testified that contaminated Salk stocks continued to be given to American children until early 1963, and that the major oral vaccine maker did not adequately test its master seed stocks. Attorney Stanley Kops testified that Wyeth-Lederle held 84 percent of the oral polio vaccine market in 1964–67 and that test results in his possession showed SV40 in released product.
- Source
- U.S. House of Representatives, Committee on Government Reform, Subcommittee on Human Rights and Wellness
- Date
- 10 September 2003
- Quoted from
- House Government Reform Committee hearing (CHRG-108hhrg91047), 10 September 2003, testimony of Stanley P. Kops, second panel
- Grade
- Primary record
- Document
- https://www.govinfo.gov/content/pkg/CHRG-108hhrg91047/html/CHRG-108hhrg91047.htm
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
- Note
- Testimony by witnesses other than federal officials is graded as reported where a finding rests on it.
7.3 How many were exposed
CDC has estimated that 10 to 30 million Americans may have received polio vaccine contaminated with SV40.
About 98 million Americans received the Salk vaccine between 1955 and 1963. CDC estimates that 10 to 30 percent of polio vaccine given in those years was contaminated with SV40. A CDC fact sheet put the number of people who may have received a contaminated dose at 10 to 30 million.
Evidence: Exhibit 112, Exhibit 113, Exhibit 114
The 98 million figure counts all recipients of the inactivated vaccine. The 10 to 30 million figure counts those who may have received a contaminated dose. Claims that 98 million people were injected with SV40 overstate the official record.
The CDC fact sheet that gave the 10 to 30 million figure, dated 2007, no longer appears on CDC's site. Copies survive in the University of North Texas end-of-term web archive and the Internet Archive. CDC's current page keeps the 10 to 30 percent estimate.
Exhibit 113 · Agency fact sheet, archived
Cancer, Simian Virus 40 (SV40), and Polio Vaccine Fact Sheet (archived)
it has been estimated that 10 - 30 million Americans could have received an SV40 contaminated dose of vaccine.
A CDC fact sheet on SV40 and polio vaccine described the contamination and estimated that 10–30 million Americans may have received a contaminated dose. The page no longer appears on CDC's site. Copies survive in the University of North Texas end-of-term web archive (2008) and the Internet Archive (2011).
- Source
- Centers for Disease Control and Prevention
- Date
- 2007; archived copies 2008 and 2011
- Quoted from
- CDC NIP fact sheet 'Simian Virus 40 (SV40), Polio Vaccine, and Cancer', 'What You Should Know', bullet 3 (UNT End of Term capture of 28 Oct 2008)
- Grade
- Primary record
- Document
- https://webarchive.library.unt.edu/eot2008/20081028051234/http://www.cdc.gov/nip/vacsafe/concerns/cancer/sv40-polio-cancer-facts.htm
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
- Note
- Snopes describes the material as moved and updated rather than deleted. The date of removal is unverified.
7.4 What the cancer studies can show
The Institute of Medicine found the evidence inadequate to accept or reject a link between contaminated polio vaccine and cancer. It found strong evidence that SV40 is a transforming virus and contaminated some 1955 to 1963 polio vaccine, and moderate evidence that vaccine exposure caused human SV40 infection.
In 2002 the Institute of Medicine's Immunization Safety Review Committee found the evidence "inadequate to accept or reject a causal relationship" between SV40-containing polio vaccines and cancer. It rated as strong the evidence that SV40 is a transforming virus and that some polio vaccine given from 1955 to 1963 was contaminated, and as moderate the evidence that vaccine exposure caused human SV40 infection. It judged the population studies too flawed to settle the question, because they assigned exposure by year of birth and contamination varied from lot to lot.
Evidence: Exhibit 114, Exhibit 115, Exhibit 111
Mechanism: The study not run
The official position
CDC: most studies of SV40 and cancer are reassuring and find no causal association between receipt of contaminated polio vaccine and cancer.
What the record shows
The principal studies compared people born in years of likely exposure with people born in other years. None had individual vaccination records. The Institute of Medicine found these studies too flawed to reject a causal link. A statement that the studies clear the vaccine goes further than the Institute of Medicine did.
The leading null study in the United States is Strickler and colleagues' 1998 cohort analysis in JAMA. It used cancer registry and mortality data and found no significant excess of brain cancer, bone cancer or mesothelioma in exposed birth cohorts. Goedert, of the National Cancer Institute, was a co-author.
At the 2003 hearing, Goedert testified that Howard Strickler was a former postdoctoral fellow from his branch and that the branch had collaborated with him on a number of projects until recently. The National Cancer Institute branch that produced the main null cohort study was also the branch whose official testified to Congress on the state of the evidence.
CDC states that no vaccine used today contains SV40 virus. That statement is correct, and the Institute of Medicine recommended no change to current vaccines on that basis.
Exhibit 114 · Consensus report
Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer
The committee found the evidence 'inadequate to accept or reject a causal relationship' between SV40-containing polio vaccines and cancer. It rated as strong the evidence that SV40 is a transforming virus and that some polio vaccine of 1955 to 1963 was contaminated, and as moderate the evidence that vaccine exposure caused human SV40 infection. It judged the epidemiological studies too flawed to settle causation, because they assigned exposure by birth cohort and contamination was uneven. It recommended a Vaccine Contamination Prevention and Response Plan and serologic tests, and no policy review of current polio vaccine because it is free of SV40.
- Source
- Institute of Medicine, Immunization Safety Review Committee
- Date
- October 2002 (published 2003)
- Grade
- Primary record
- Document
- https://nap.nationalacademies.org/catalog/10534
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
7.5 Oral vaccine after 1963
Testimony to Congress in 2003 stated that some oral polio vaccine released between 1964 and 1967 still contained SV40.
Attorney Stanley Kops testified at the 2003 hearing that Wyeth-Lederle held 84 percent of the American oral polio vaccine market between 1964 and 1967. He testified that the company's vaccine "did contain SV-40," citing test results in his possession that showed "the positive vacuolating agent in released product."
Evidence: Exhibit 111
Mechanism: Known inside, disclosed late
Kops's account of those test results rests on his testimony. Fisher testified at the same hearing that the major oral vaccine maker had not adequately tested its master seed stocks. CDC's page states that contamination was found in oral as well as inactivated vaccine. It gives no end date for oral vaccine contamination.
7.6 EcoHealth and the late report
NIAID funded EcoHealth Alliance's coronavirus work with the Wuhan Institute of Virology. EcoHealth reported an experiment that made mice sicker nearly two years late, and HHS debarred it and Peter Daszak in January 2025.
On 27 May 2014 NIAID awarded grant R01AI110964, "Understanding the Risk of Bat Coronavirus Emergence," to EcoHealth Alliance, with the Wuhan Institute of Virology as a consortium participant. From 2018 the award required EcoHealth to notify NIAID immediately of any experiment that increased virus growth more than tenfold over wild type. EcoHealth's Year 5 progress report was due on 30 September 2019 and was submitted on 3 August 2021. NIH found that an experiment it described had possibly exceeded that threshold, and that EcoHealth had not notified NIAID.
Evidence: Exhibit 116, Exhibit 117
Mechanism: Known inside, disclosed late
| Date | Event |
|---|---|
| 27 May 2014 | NIAID awards the grant; Wuhan Institute of Virology listed as consortium participant |
| 28 May 2016 | NIAID writes to EcoHealth about possible gain-of-function research under the 2014 funding pause |
| 18 June 2018 | Renewal requires immediate notice of any virus with growth more than 1 log above wild type |
| 30 September 2019 | Year 5 progress report due |
| 3 August 2021 | EcoHealth submits the Year 5 report, nearly two years late |
| 20 October 2021 | NIH writes to EcoHealth and to Congress about the experiment |
| 15 May 2024 | HHS suspends EcoHealth and proposes debarment |
| 17 January 2025 | HHS debars EcoHealth and Peter Daszak for five years; EcoHealth ineligible through 14 May 2029 |
FactCheck.org quotes the NIH letter to Congress of 20 October 2021, from NIH's principal deputy director, Lawrence Tabak. The letter states that in a "limited experiment" under the grant, mice infected with a chimeric SHC014/WIV1 bat coronavirus became sicker than mice infected with WIV1, and that EcoHealth had failed to report the finding as the grant required. FactCheck.org reports that NIH maintained that the work did not meet its definition of enhanced potential pandemic pathogen research.
HHS's Suspension and Debarment Official found debarment necessary to protect the Federal Government's interests. The memorandum lists EcoHealth's failure to give immediate notice of the experiment, its late progress report, its inaccurate claim that the experiments in the Year 4 and Year 5 reports were the same, its failure to take active steps to obtain records from the Wuhan laboratory, and its claim that a computer lockout caused the delay. EcoHealth ended Daszak's employment effective 6 January 2025. The debarment memorandum does not address the origin of SARS-CoV-2.
Exhibit 116 · Agency debarment decision
Notice of Debarment and Action Referral Memorandum for Final Debarment, EcoHealth Alliance, Inc.
NIAID awarded grant 1R01AI110964, 'Understanding the Risk of Bat Coronavirus Emergence,' to EcoHealth Alliance on 27 May 2014 (project period 1 June 2014 to 31 May 2019), with the Wuhan Institute of Virology as a consortium participant. From 2018 the award required immediate notification of any experiment producing virus growth more than 1 log above wild type. EcoHealth submitted its Year 5 progress report on 3 August 2021, nearly two years after it was due; NIH found that an experiment in it had possibly produced a greater than 1 log increase and that EcoHealth had not notified NIAID. HHS suspended EcoHealth on 15 May 2024 and debarred it for five years, through 14 May 2029, finding debarment necessary to protect the Federal Government's interests. The memorandum (para 35) says the experiments led to 'substantially greater mortality rates.' It lists as grounds the failure to follow the immediate-reporting requirement, the late progress report, an inaccurate claim that the Year 4 and Year 5 experiments were the same, failure to take active steps to obtain records from the Wuhan Institute of Virology, and the claim that a computer lockout caused the delay; NIH's forensic review contradicted the lockout claim (para 44). EcoHealth ended Peter Daszak's employment effective 6 January 2025.
- Source
- U.S. Department of Health and Human Services, Suspension and Debarment Official
- Date
- 17 January 2025
- Grade
- Primary record
- Document
- https://oversight.house.gov/wp-content/uploads/2025/01/ARM_EHA_1.17.2025_Redacted.pdf
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
- Note
- HHS document as released, redacted, by the House Committee on Oversight. The memorandum carries no date of its own; 17 January 2025 comes from the file name and the Committee's release. Parallel notice for Peter Daszak: https://oversight.house.gov/wp-content/uploads/2025/01/Dr.-Peter-Daszak-HHS-Notice_Jan-17-2025_Redacted.pdf; notice to EcoHealth: https://oversight.house.gov/wp-content/uploads/2025/01/Notice-_EHA_1.17.2025_Redacted.pdf
7.7 Myocarditis: signal to label
CDC data showed the myocarditis signal in young males in 2021. FDA put age-specific risk figures and evidence of persistent heart injury on the labels in June 2025.
In July 2021 CDC reported VAERS rates of myocarditis within a week of the second mRNA dose of about 40.6 per million doses in males aged 12 to 29, against 2.4 per million in males 30 and older. Myocarditis information has been in the vaccine labels since 2021. In June 2025 FDA required an updated warning stating that risk was highest in males 12 through 24, with an estimate of about 27 cases per million doses in that group, and citing an FDA-funded study showing persistent heart injury on MRI.
Evidence: Exhibit 118, Exhibit 119, Exhibit 120
Mechanism: Known inside, disclosed late
| Measure | Result |
|---|---|
| Patients hospitalized with myocarditis after vaccination | 333 |
| Late gadolinium enhancement on initial cardiac MRI | 82% (177/216) |
| Enhancement still present at median 159 days, among those with initial enhancement | 60% (98/161) |
Late gadolinium enhancement is a marker of injury to the heart muscle. The FDA-funded study was published in September 2024. The label update came nine months after that publication and four years after CDC's first report of the signal. The FDA commissioner and its vaccine chief wrote in JAMA in 2025 that the labeling change should not be seen as a final resolution of the concern. The FDA-sponsored follow-up reports outcomes to a median of 159 days.
Exhibit 120 · Journal article by agency officials
US FDA Safety Labeling Change for mRNA COVID-19 Vaccines
The FDA's vaccine chief and commissioner described the evidence for the June 2025 labeling change. An FDA-sponsored retrospective study included 333 patients hospitalized with myocarditis after COVID-19 vaccination. Of cases evaluated by cardiac MRI, 82% (177/216) showed late gadolinium enhancement, a marker of myocardial injury; of those with initial enhancement, 60% (98/161) still showed it at a median of 159 days. The authors wrote that the labeling change should not be seen as a final resolution of the concern.
- Source
- Vinay Prasad and Martin A. Makary, U.S. Food and Drug Administration; JAMA 334(11):945–946
- Date
- 2025 (JAMA 2025;334(11):945-946)
- Grade
- Primary record
- Document
- https://doi.org/10.1001/jama.2025.12675
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
7.8 The child-death count
According to NBC News, an FDA official attributed at least 10 child deaths to COVID-19 vaccines in a November 2025 memo. FDA's own review in May 2026 rated 5 possible, 2 probable and none certain.
According to NBC News, a November 2025 memo to FDA staff from Vinay Prasad, head of the agency's vaccine center, stated that at least 10 of 96 child deaths reported to VAERS from 2021 to 2024 were related to COVID-19 vaccination. NBC reported that the memo did not include the children's ages or medical histories, timelines or documentation for the deaths. In May 2026 an FDA review of the deaths rated none certain, 5 possible and 2 probable, and stated that these categories do not establish causation.
Evidence: Exhibit 121, Exhibit 122
A black-box warning was reportedly considered in December 2025. Commissioner Makary later said FDA was not considering one, and none was added. The 2025 memo's count was larger than the count FDA's 2026 review supported.
7.9 The SV40 element in Pfizer's plasmid
Pfizer submitted its full plasmid sequence to Health Canada. According to reports of a Health Canada email, Pfizer did not specifically identify the SV40 promoter-enhancer element it contained.
The DNA plasmid used to make Pfizer's mRNA vaccine contains an SV40 promoter-enhancer, a short regulatory sequence taken from the virus. Kevin McKernan reported it in April 2023. Health Canada's answer to Order Paper Question Q-1954 states that Pfizer provided the full plasmid sequence at its initial filing and that the SV40 promoter-enhancer fragment "is inactive, has no functional role." Reports in The Epoch Times and advocacy outlets quote a Health Canada email as saying that Pfizer "did not specifically identify the SV40 sequence" and that Health Canada confirmed the element from Pfizer's submitted sequence after it was raised publicly.
Evidence: Exhibit 123
Mechanism: Known inside, disclosed late
The element is a fragment of regulatory DNA. It contains no SV40 virus and no T-antigen gene, the part of SV40 associated with tumors in animals. Health Canada described it as inactive with no functional role. Residual plasmid DNA in the vaccine is a separate dispute over quantity and measurement method.
The "did not specifically identify" wording appears in reports by The Epoch Times and advocacy outlets, which quote it consistently. Health Canada's parliamentary answer does not contain it.
7.10 Two approvals with the data in print
Two drug approvals show the comparison case, in which the adverse data were published when the product reached the public. In July 1987 the New England Journal of Medicine published the pivotal AZT trial together with a companion report on its toxicity. Multiple red-cell transfusions were needed by 21 percent of AZT recipients and 4 percent of placebo recipients. Hemoglobin fell below 7.5 g/dL in 24 percent and 4 percent, and neutropenia occurred in 16 percent and 2 percent.
Exhibit 124 · Randomized trial report
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial
Twenty-one percent of AZT recipients and 4 percent of placebo recipients required multiple red-cell transfusions (P less than 0.001).
The companion toxicity report to the pivotal AZT trial, published in the same issue. Multiple red-cell transfusions were needed by 21% of AZT recipients and 4% of placebo recipients; hemoglobin fell below 7.5 g/dL in 24% and 4%; neutropenia occurred in 16% and 2%.
- Source
- Douglas D. Richman et al., New England Journal of Medicine 317(4):192–197
- Date
- 23 July 1987
- Quoted from
- Abstract (N Engl J Med 1987;317:192-7)
- Grade
- Peer-reviewed
- Document
- https://doi.org/10.1056/NEJM198707233170402
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
On 22 October 2020 FDA approved remdesivir for hospitalized COVID-19 patients. Its announcement reported that NIAID's ACTT-1 trial shortened median recovery from 15 days to 10. The announcement did not report the trial's mortality result. The final report, published in November 2020, gave day-29 mortality of 11.4 percent on remdesivir and 15.2 percent on placebo, a difference that was not statistically significant (hazard ratio 0.73, 95% CI 0.52–1.03).
Exhibit 125 · Agency press announcement
FDA Approves First Treatment for COVID-19
The median time to recovery from COVID-19 was 10 days for the Veklury group compared to 15 days for the placebo group, a statistically significant difference.
FDA approved remdesivir (Veklury) for hospitalized COVID-19 patients. The announcement reported that in ACTT-1 the median time to recovery was 10 days on remdesivir and 15 days on placebo. It did not report ACTT-1's mortality result.
- Source
- U.S. Food and Drug Administration
- Date
- 22 October 2020
- Quoted from
- FDA news release, 22 Oct 2020, paragraph on ACTT-1
- Grade
- Primary record
- Document
- https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
Exhibit 126 · Randomized trial report
Remdesivir for the Treatment of Covid-19 — Final Report
The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03).
NIAID's trial randomized 1,062 hospitalized patients. Median recovery was 10 days on remdesivir and 15 on placebo (rate ratio 1.29, 95% CI 1.12–1.49). Day-29 mortality was 11.4% and 15.2% (hazard ratio 0.73, 95% CI 0.52–1.03), a difference that was not statistically significant. Serious adverse events were less frequent on remdesivir (24.6% vs 31.6%).
- Source
- John H. Beigel et al. (ACTT-1 Study Group), New England Journal of Medicine 383(19):1813–1826
- Date
- 5 November 2020
- Quoted from
- Abstract, Results (N Engl J Med 383:1813-26)
- Grade
- Peer-reviewed
- Document
- https://doi.org/10.1056/NEJMoa2007764
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit
7.11 From internal knowledge to public record
| Case | Known | By whom | What was done | What the public was told |
|---|---|---|---|---|
| Cutter live virus | 1954 or spring 1955 | Eddy; Workman; reportedly Sebrell | Results not sent to the licensing committee; Cutter licensed 12 April 1955 | Vaccine licensed; hazard learned through cases in April–May 1955 |
| SV40 in polio vaccine | 1960 | Sweet and Hilleman; Eddy; Smadel; federal biologics officials | New lots screened from 1961; no recall; all lots certified from 1963 | CDC now reports 10–30% of 1955–63 doses contaminated |
| SV40 and cancer | 2002 | Institute of Medicine | Evidence judged inadequate to accept or reject a link | CDC: most studies reassuring |
| EcoHealth experiment | Due by 30 September 2019 | EcoHealth; Wuhan Institute of Virology | Report filed 3 August 2021; debarment 17 January 2025 | NIH letter to Congress, 20 October 2021 |
| mRNA myocarditis | 2021 | CDC; FDA | Warning in labels from 2021; age-specific figures and MRI data added June 2025 | June 2025 label update |
| Child-death count | November 2025 | FDA vaccine center | Internal memo claimed at least 10; May 2026 review rated 5 possible, 2 probable | Memo reported by press; review reported May 2026 |
| SV40 element in plasmid | At filing | Pfizer | Full sequence submitted without the element identified | Health Canada reportedly confirmed it after public reports |
In the polio cases the interval between internal knowledge and public account ran to decades. Eddy's monkey results surfaced through her oral history and later histories. The decision not to recall SV40-contaminated stock entered the public record through congressional testimony in 2003 and a book in 2004.
In the recent cases the interval is measured in months or years. Each record became public through a regulator, a congressional committee or an outside researcher. EcoHealth's report reached NIH nearly two years late. FDA's MRI evidence reached the label nine months after publication. The SV40 element in Pfizer's plasmid was identified by an outside genomics researcher before the regulator named it.
Related histories
The chronology continues in Chapter 11: Industrial Poisons and Delayed Disclosure, Chapter 12: Military Exposure and the Classified Record, and Chapter 13: Patients Against the Official Record. Each case separates the dates of exposure, warning, disclosure and institutional action.
Key findings
- An NIH scientist's finding that Cutter lots paralyzed monkeys did not reach the licensing committee (7.1).
- Officials knew of SV40 in polio vaccine by 1960, screened only new lots from 1961, recalled nothing, and certified all lots only from 1963 (7.2).
- CDC estimated that 10 to 30 million Americans may have received contaminated doses (7.3).
- The Institute of Medicine found the evidence inadequate to accept or reject a cancer link, and rated the evidence that vaccine exposure caused human infection as moderate (7.4).
- Testimony placed SV40 in released oral polio vaccine as late as 1967 (7.5).
- EcoHealth reported a Wuhan experiment nearly two years late and was debarred in 2025 (7.6).
- The myocarditis signal appeared in 2021; age-specific risk and persistent MRI injury reached the labels in 2025 (7.7).
- An internal FDA count of child deaths exceeded what the agency's own review supported (7.8).
- According to reports of a Health Canada email, Pfizer did not identify the SV40 element in the plasmid sequence it filed with Health Canada (7.9).